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Abstract 
Background: Insulin-like growth factors (IGFs) and their binding proteins (BPs) 
regulate cell differentiation, proliferation and apoptosis and may play a role in 
the aetiology of various cancers. Information on their role in pancreatic cancer is 
limited and was examined here in a case-control study nested within the 
European Prospective Investigation into Cancer and Nutrition (EPIC). 
Methods: Serum concentrations of IGF-I and IGFBP-3 were measured using 
enzyme-linked immunosorbent assays in 422 cases and 422 controls matched 
on age, sex, study centre, recruitment date, and time since last meal. 
Conditional logistic regression was used to compute odds ratios (OR) and 95% 
confidence intervals (CI) adjusted for confounding variables. 
Results: Neither circulating levels of IGF-I (OR=1.21, 95% CI 0.75-1.93 for top 
vs. bottom quartile, p-trend 0.301), IGFBP-3 (OR=1.00, 95% CI 0.66-1.51, p-
trend 0.79), nor the molar IGF-I/IGFBP-3 ratio, an indicator of free IGF-I level 
(OR=1.22, 95% CI 0.75-1.97, p-trend 0.27), were statistically significantly 
associated with the risk of pancreatic cancer. In a cross-classification, however, 
a high concentration of IGF-I with concurrently low levels of IGFBP-3 was 
related to an increased risk of pancreatic cancer (OR=1.72, 95% CI 1.05-2.83; 
p-interaction=0.154). 
Conclusion: Based on these results, circulating levels of components of the 
insulin-like growth factor axis do not appear to be risk factors for pancreatic 
cancer. However, based on the results of a subanalysis it cannot be excluded 
that a relatively large amount of IGF-1 together with very low levels of IGFBP-3 
might still be associated with an increase in pancreatic cancer risk. 
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Introduction 1 
Pancreatic cancer is one of the most common causes of cancer deaths in the 2 
Western world. In Europe, 48,300 deaths in men and 46,900 deaths in women due to 3 
pancreas cancer were estimated for 2008 (Ferlay et al, 2010). So far, only few risk 4 
factors for pancreatic cancer have been clearly identified. Smoking is the major 5 
established lifestyle factor known to cause pancreatic cancer accounting for up to 25-6 
30% of all pancreas cancer cases (Lowenfels & Maisonneuve, 2004). Some nutrition-7 
related factors have also been found to be associated with pancreas cancer risk, 8 
including excess body weight (Berrington de Gonzalez et al, 2003; Jiao et al, 2010), 9 
history of type-2 diabetes mellitus (Huxley et al, 2005), elevated blood levels of 10 
glucose (Batty et al, 2004; Gapstur et al, 2000; Grote et al, 2011; Jee et al, 2005; 11 
Stattin et al, 2007; Stolzenberg-Solomon et al, 2005) and, possibly, chronic 12 
hyperinsulinemia (Stolzenberg-Solomon et al, 2005).  13 
Insulin-like growth factors (IGFs) are multifunctional peptides that regulate cell 14 
proliferation, differentiation, and apoptosis (Khandwala et al, 2000). IGF-I is an 15 
important regulator of cell growth in the postnatal period (Khandwala et al, 2000). 16 
Binding proteins (IGFBP-1 through IGFBP-6) modulate the biological effects of IGF-I 17 
as they determine the concentration of biologically active, unbound IGF (Jones & 18 
Clemmons, 1995). More than 90% of circulating IGF-I is bound to IGFBP-3 and less 19 
than 1% circulates in free form (Grimberg & Cohen, 2000). Binding of IGF-I to the 20 
IGF-I receptor leads to stimulation of mitogenesis in a number of cell types, to cellular 21 
protection from apoptosis, and to cellular transformation (Grimberg & Cohen, 2000). 22 
IGFBP-3 has growth-inhibiting properties by competitively binding IGF-I, but it also 23 
has independent growth inhibiting effects, e.g. via induction of apoptosis (Rajah et al, 24 
2002; Rajah et al, 1997). IGFBP activities are, among others, regulated by IGFBP 25 
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proteases, which may cleave IGFBPs into fragments with lower affinity to IGFs (Nunn 1 
et al, 1997).  2 
Ohmura et al. (Ohmura et al, 1990) have shown that IGF-I can stimulate 3 
pancreatic cancer cell growth in vitro, and that this effect is mediated by the IGF-I 4 
receptor (Bergmann et al, 1995). The analysis of pancreatic cancer tissue revealed 5 
increased IGF-I mRNA and IGF-I receptor mRNA levels compared with tissue of 6 
healthy individuals (Bergmann et al, 1995). Similarly, increased levels of IGF-I and 7 
increased IGF-I receptor expression were observed in pancreatic cancer tissue 8 
compared with normal pancreas tissue (Karna et al, 2002). It appears that IGF-I 9 
stimulation and subsequent suppression of tumour suppressor chromosome 10 10 
(PTEN) activity enhance invasiveness and proliferation of pancreatic cancer cells 11 
(Ma et al, 2010).  12 
Circulating levels of IGF-1 and IGF binding proteins have been found to be 13 
associated with several types of cancers, including colon (Rinaldi et al, 2010), 14 
prostate (Roddam et al, 2008), and breast cancer (The Endogenous Hormones and 15 
Breast Cancer Collaborative Group, 2010). However, the number of studies 16 
conducted with respect to pancreatic cancer is limited as is the number of cases in 17 
these studies. The results of the prospective studies are rather inconsistent, 18 
however, with most studies showing no association of circulating IGF-I or IGFBP-3 19 
levels with pancreatic cancer risk (Douglas et al, 2010; Lin et al, 2004; Stolzenberg-20 
Solomon et al, 2004; Wolpin et al, 2007). Because of the inconsistencies of previous 21 
studies, we examined the association between IGF-I, IGFBP-3 and pancreatic cancer 22 
in the prospective EPIC cohort including more than 400 incident cases of pancreatic 23 
cancer. 24 
 25 
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Material and Methods 1 
Study description 2 
EPIC is a prospective cohort study that includes more than 500,000 male and 3 
female participants recruited in 23 centres in 10 European countries between 1992 4 
and 2000. Most centres recruited subjects from the general population, but in Utrecht 5 
and Florence only women from breast cancer screening programs were recruited; the 6 
Spanish and Italian centres include blood donors and the French cohort consists of 7 
members of a health insurance for state school employees. A high proportion of 8 
participants of the Oxford cohort are vegetarians or health-conscious volunteers. The 9 
cohorts of France, Utrecht, Florence, and Norway include women only. 10 
Information on lifestyle and diet was collected during baseline examination. 11 
Diet was assessed using country-specific validated dietary assessment instruments 12 
(Kaaks et al, 1997; Riboli & Kaaks, 1997). Information on smoking, alcohol 13 
consumption, physical activity, education, occupation, and medical and reproductive 14 
history has been collected using questionnaires and personal interviews. 15 
Anthropometric measurements have been conducted during baseline examination 16 
(Haftenberger et al, 2002).  17 
Following a standardized protocol, a blood sample of 30 mL was collected in 18 
all participating EPIC countries. In all centres except Oxford, blood samples were 19 
stored protected from light at 5-10°C until further processing and aliquoting. In the 20 
Oxford centre, blood samples were collected throughout the United Kingdom and 21 
transported to the laboratory in Norfolk by mail at ambient temperature. In all centres 22 
except Denmark and Sweden, 0.5-1.5 ml aliquots of serum, plasma, red blood cells, 23 
and buffy coat were filled into plastic straws and stored in liquid nitrogen at -196°C. In 24 
the Danish centres, 1 ml aliquots were filled into tubes and stored in the vapour 25 
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phase of liquid nitrogen containers (-150°C). In Sweden, the samples were stored at -1 
80°C. 2 
Selection of Case and Control Subjects 3 
Pancreatic cancer incidence data were coded according to ICD-10 and 4 
included all invasive exocrine pancreatic cancers that were coded as C25 (25.0-25.3, 5 
25.7-25.9). Cases were those EPIC participants who developed pancreatic cancer 6 
after their recruitment into the cohort and before the end of the study period. 7 
Individuals were excluded when diagnosed with another malignant tumour prior to 8 
the diagnosis of pancreatic cancer, except for non-melanoma skin cancer, and when 9 
no blood specimens were available for analysis. 638 incident cases of pancreatic 10 
cancer occurred until December 2006; 578 of them were primary exocrine pancreatic 11 
tumours. Blood specimens were available for 422 of these cases. The included 422 12 
pancreatic cancer cases were similar in their characteristics to the overall 578 cases 13 
with pancreatic adenocarcinoma (data not shown). Of the 422 cases, 307 (76%) 14 
were microscopically confirmed. The remaining 24% were diagnosed by clinical 15 
symptoms, imaging results or physical examination. Forty-one percent of the tumours 16 
occurred in the head of the pancreas, followed by body (7%) and tail (5%); the rest of 17 
the tumours were of unknown localization. One control, alive and free of cancer at 18 
time of diagnosis of the index case, was selected for each case using incidence 19 
density sampling, i.e., controls may include subjects who became a case later in time 20 
and each control may be sampled more than once. Cases and controls were 21 
matched by study centre, sex, age at enrolment (± 6 months), date at entry in the 22 
cohort, time between blood sampling and time of last consumption of foods and 23 
drinks (<3 hours, 3-6 hours, > 6 hours). 24 
Laboratory assays 25 
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Serum IGF-I and IGFBP-3 concentrations were measured in the immunoassay 1 
laboratory at the German Cancer Research Center (DKFZ), Heidelberg, Germany. 2 
Both peptides were analyzed by enzyme-linked immunosorbent assays (ELISAs) 3 
purchased from Beckman Coulter. Prior to total IGF-I analysis, IGF-I was separated 4 
from IGF-I binding proteins by an acid-ethanol extraction step. Cases and matched 5 
controls were measured in singleton within the same batch. Each analytical batch 6 
further included three different serum quality control samples. Laboratory staff was 7 
blinded to the case/control status of the study samples. Intra-batch and inter-batch 8 
coefficients of variation for IGF-I and IGFBP-3 were 12.8 and 12.9%, and 6.5 and 9 
7.2%, respectively. 10 
Statistical analysis 11 
Conditional logistic regression was used to examine the associations of IGF-I 12 
and IGFBP-3 concentrations with pancreatic cancer risk. We also computed the 13 
molar ratio of IGF-I to IGFBP-3 (IGF-I/IGFBP-3 ratio) as a marker of the estimated 14 
level of IGF-I biologically available to bind to its receptor. Concentrations of IGF-I and 15 
IGFBP-3 as well as IGF-I/IGFBP-3 ratio were categorized into sex-specific quartiles 16 
based on the distribution among all controls. Crude models took into account 17 
matching criteria; multivariate models were additionally adjusted for body mass index 18 
(BMI; continuous), smoking history (never, former, quitting smoking less than 10 19 
years ago, more than 10 years ago, current, with 1-9, 10-19, or ≥ 20 cigarettes per 20 
day, missing), and history of diabetes (self-reported or high glycated haemoglobin 21 
(HbA1c) concentration [≥ 6.5%]). These covariates were added in the multivariable 22 
adjusted models because they were associated with pancreatic cancer, correlated 23 
with IGF-1 or IGFBP-3, or changed the logistic β estimate by more than 10%. Further 24 
adjustment was made for circulating C-peptide concentration, which has been 25 
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measured previously on the same subjects (Grote et al, 2011). Further analyses 1 
were conducted with mutual adjustments between IGF-I and IGFBP-3 2 
concentrations. 3 
Sub-analyses were performed, stratified by sex, smoking status at baseline 4 
(smoker/non-smoker), diabetes (defined by self-report or HbA1c concentrations (≥ 5 
6.5%), waist circumference (</≥ median; 96 cm for men and 80 cm for women), 6 
length of follow-up (≤/>2 year of follow-up time in cases), concentration of C-peptide 7 
(</≥ median, 5.57 ng/mL), and microscopically verification of cases. Odds ratios (OR) 8 
were estimated for quartiles of IGF-1 and IGFBP-3 concentrations as well as IGF-9 
I/IGFBP-3 ratio. Additionally, we examined the interaction between IGF-I and IGFBP-10 
3 levels (both variables were dichotomized by median concentration) in a cross-11 
classification. Statistical tests for heterogeneity were based on chi-square statistics, 12 
calculated as the deviations of logistic beta-coefficients observed in each of the 13 
subgroups, relative to the overall beta-coefficient. All analyses were conducted with 14 
SAS version 9.2. 15 
 16 
Results 17 
Of 422 cases in this analysis, 46% were men (Table 1). Mean age at baseline was 58 18 
years; mean age at diagnosis 63 years. Female cases had a higher BMI and waist 19 
circumference than female controls, but no difference was observed among men. 20 
Cases were more often smokers at baseline than controls and they more often 21 
reported a diagnosis of diabetes at baseline or had elevated baseline blood levels of 22 
HbA1c. IGF-1 was not statistically significantly correlated with BMI (Pearson partial 23 
correlation coefficient; adjusted for age, sex, and study centre; r = -0.07 [95% CI -24 
0.17 to 0.03]), waist circumference (r = -0.03 [95% CI -0.13 to 0.08]), or circulating C-25 
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peptide level (0.10 [95% CI -0.005 to 0.20]), and rather weakly with height (r = 0.11 1 
[95% CI 0.01 to 0.21]); whereas IGFBP-3 showed correlations with BMI (r = 0.12 2 
[95% CI 0.01 to 0.22]), waist circumference (r = 0.13 [95% CI 0.03 to 0.23]), and C-3 
peptide levels (r = 0.20 [95% CI 0.10 to 0.30]), but not with height (r = 0.01 [95% CI -4 
0.09 to 0.12]). IGF-1 correlated highly and significantly with IGFBP-3 (r = 0.52 [95% 5 
CI 0.44 to 0.59]) and the molar IGF-1/IGFBP-3 ratio (r = 0.78 [95% CI 0.74 to 0.82]), 6 
whereas the ratio showed no correlation with IGFBP-3 (r = -0.09 [95% CI -0.19 to 7 
0.01]). 8 
Circulating levels of IGF-I or IGFBP-3 were not related to the risk of pancreatic 9 
cancer (Table 2). Using molar IGF-I/IGFBP-3 ratio as an indicator of free IGF-I 10 
concentration, we also observed no association with pancreatic cancer risk. The 11 
results were only slightly affected by different types of adjustment. Additional mutual 12 
adjustment of IGF-I and IGFBP-3 also did not strongly change the observed 13 
associations with pancreatic cancer. There were also no associations of IGF-I, 14 
IGFBP-3 or the ratio of these two with pancreatic cancer, when using only 15 
microscopically confirmed cases (Table 3). 16 
In sub-analyses, we examined whether the association of IGF-I, IGFBP-3, or 17 
IGF-I/IGFBP-3 with pancreatic cancer was modified by sex, smoking status, length of 18 
follow-up, waist circumference, diabetes status, or circulating C-peptide 19 
concentration (Table 3). With few exceptions, we did not observe statistically 20 
significant heterogeneity between subgroups. Waist circumference modified the 21 
association of IGF-1 and IGF-1/IGFBP-3 ratio with pancreatic cancer risk, such that 22 
IGF-1 concentration were positively associated with pancreatic cancer in subjects 23 
with low waist circumference when comparing quartile 3 with quartile 1; no 24 
association was observed when comparing top vs. bottom quartile. There were no 25 
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statistically significant associations among individuals with waist circumference below 1 
above the median. 2 
We cross-classified IGF-I and IGFBP-3 concentration and observed an 3 
increased risk of pancreatic cancer among those with IGF-I concentration above the 4 
median and IGFBP-3 concentration below the median (OR=1.72, 95% CI 1.05-2.83); 5 
however, the test for interaction was not statistically significant (p=0.154; Table 4). 6 
 7 
Discussion 8 
We examined the association of components of the IGF axis in association 9 
with the risk of pancreatic cancer in the largest prospective study so far without 10 
finding any indication for an association with circulating levels of IGF-I and IGFBP-3. 11 
There was, however, an increased risk among those with high IGF-I and concurrently 12 
low IGFBP-3 concentrations, although the interaction was not statistically significant. 13 
Evans et al (Evans et al, 1997) found no elevated serum levels of IGF-I and IGFBP-3 14 
in pancreatic cancer compared with controls. In contrast, Karna et al (Karna et al, 15 
2002) showed significant increases in serum IGF-I and IGFBP-3 levels in patients 16 
with pancreatic cancer compared with control subjects. Among prospective studies, a 17 
case-control study nested within the ATBC trial did not observe associations of 18 
serum concentrations of IGF-1, IGFBP-3 or IGF-1/IGFBP-3 ratio with the risk of 19 
pancreatic cancer (Stolzenberg-Solomon et al, 2004); however, this result is based 20 
on a cohort of male smokers only. This null association, though, is similar to the 21 
results seen in four US cohorts that were analysed together (Wolpin et al, 2007). 22 
Only a nested case-control study conducted in Japan reported that individuals in the 23 
highest quartile of IGF-I concentration had an OR of 2.31 (0.70-2.64) compared with 24 
participants in the lowest quartile (Lin et al, 2004). A recently published study nested 25 
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in the PLCO cohort observed an increased risk of pancreatic cancer with increasing 1 
IGF-I/IGFBP-3 molar ratio, which was interpreted as an indicator of the concentration 2 
of free IGF-I (Douglas et al, 2010). We did not observe an increase in risk with 3 
increasing IGF-I/IGFBP-3 molar ratio, but did observe that those participants with 4 
high IGF-I levels above the median and low IGFBP-3 concentrations had an 5 
increased risk of pancreatic cancer. 6 
IGFBP-3 is supposed to have growth inhibiting properties and one would, thus, 7 
expect that high IGFBP-3 concentrations are inversely associated with cancer risk. 8 
On the other hand, IGFBP-3 and IGF-I are highly correlated in our cohort. In the 9 
Japanese nested case-control study, IGFBP-3 concentration was positively 10 
associated with pancreatic cancer risk; the risk of death from pancreatic cancer was 11 
increased with increasing levels of serum IGFBP-3, with the OR for the highest 12 
quartile being 2.53 (95% CI=0.93-6.85) (Lin et al, 2004). However, the results of 13 
previous studies on different types of cancer have been inconsistent with some 14 
studies indeed showing inverse associations, but some also showing no or even a 15 
positive association (Renehan et al, 2004). Cleavage of IGFBPs by proteases results 16 
in IGFBP fragments with lower affinity to IGFs and additionally influences IGF-I 17 
bioavailability by reducing the amount of functional IGFBPs. It has been suggested 18 
that the maintenance of normal IGFBP levels is critical to normal rates of cell growth 19 
and cell death (Firth & Baxter, 2002; Nunn et al, 1997). It has also been discussed 20 
that different assays measuring concentrations of total or intact IGFBP-3 could cause 21 
differences between studies (Kaaks et al, 2001; Renehan et al, 2004; Rinaldi et al, 22 
2005). We measured intact IGFBP-3, not total IGFBP-3, which also includes IGFBP-23 
3 fragments that are less biologically active. 24 
15 
 
Most IGF-I in the circulation is produced by the liver (Pollak et al, 2004). A 1 
major factor stimulating the hepatic production of IGF-I and IGFBP-3 is growth 2 
hormone (GH) (Jones & Clemmons, 1995), but insulin also plays a central role in 3 
regulating levels of IGF-I and IGFBPs. For example, insulin increases the hepatic 4 
levels of growth hormone receptors, thereby enhancing liver synthesis of IGF-I, and 5 
in addition insulin increases bioactivity of IGF-I by inhibiting the synthesis of IGFBP-1 6 
(Kaaks & Lukanova, 2001; Lee et al, 1997). Therefore, we stratified our analysis by 7 
circulating C-peptide concentration to evaluate whether the association between IGF-8 
1 and IGFBP-3 and pancreatic cancer was different in individuals with high or low C-9 
peptide levels. However, we observed no statistically significant interaction, which is 10 
similar to what Wolpin et al. had observed in their analysis (Wolpin et al, 2007). We 11 
also examined whether other factors that are either well-known risk factors for 12 
pancreatic cancer or are associated with IGF-I concentration modified the effect of 13 
IGF-I or IGFBP-3 on pancreatic cancer risk. However, none of the factors examined 14 
modified the observed association. We only observed statistically significant 15 
interactions of waist circumference with levels of IGF-I or IGF-I/IGFBP-3 ratio, but the 16 
associations in the respective subgroups were not consistently statistically significant.  17 
In the EPIC cohort, only one blood sample has been collected at baseline. It 18 
might be that repeated measurements of IGF-I and IGFBP-3 more accurately reflect 19 
circulating levels at different points in time. However, single serum measurements of 20 
IGF-I and IGFBP-3 generally have been found to be quite representative of serum 21 
concentrations over longer time periods. In a study within the New York University 22 
Women’s Health Study cohort, Spearman’s rank correlations between repeat 23 
measurements in serum samples collected over time periods of more than one year 24 
were 0.87 and 0.73, respectively, for IGF-I and IGFBP-3 (Lukanova et al, 2004). 25 
16 
 
Other research groups have reported similar levels of reproducibility for circulating 1 
IGF-I and IGFBP-3 (Chan et al, 1998; Goodman-Gruen & Barrett-Connor, 1997).  2 
In conclusion, our results generally do not support the hypothesis that 3 
circulating levels of IGF-1 and IGFBP-3 or the molar IGF-I/IGFBP-3 ratio are 4 
associated with the risk of pancreatic cancer, which confirms the results of most 5 
previous prospective studies. However, it is noteworthy that individuals with high 6 
circulating IGF-I and low IGFBP-3 levels have an increased risk of pancreatic cancer 7 
compared to those with low IGF-I and high IGFBP-3 concentration. 8 
 9 
 10 
  11 
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Table 1. Baseline characteristics of pancreatic cancer cases and matched controls 
 
Variable Cases (n=422) Controls (n=422) 
   
Male subjects, n (%) 195 (46) 195 (46) 
Age at recruitment (y), mean (range) 58 (30-76) 58 (30-76) 
Age at diagnosis (y), mean (range) 63 (37-82) - 
Follow-up (y), mean (range) 5.4 (0-13)  
BMI (kg/m2), mean ± SD   
     Male 26.8 ± 3.6 26.7 ± 3.7 
     Female 26.5 ± 4.9 25.2 ± 4.2 
Height (cm), mean ± SD   
     Male 174.6 ± 7.4 175.1 ± 7.7 
     Female 162.3 ± 6.6 161.5 ± 7.2 
Waist circumference (cm), mean ± SD   
     Male 96.2 ± 10.1 96.6 ± 10.3 
     Female 84.3 ± 12.3 81.1 ± 10.6 
Smoking status, n (%)1   
     Never 155 (37) 189 (45) 
     Former 130 (31) 137 (32) 
     Current 132 (31) 91 (22) 
Education, n (%)1   
     Primary school or less 165 (40) 158 (39) 
     University 82 (20) 86 (21) 
Physical activity, n (%)1   
     Active 62 (16) 60 (16) 
     Inactive 103 (27) 119 (31) 
   
Alcohol intake at recruitment (g/d), mean ± SD   
     Male 19.7 ± 24.4 20.4 ± 26.2 
     Female 9.1 ± 13.1 7.4 ± 10.6 
Fasting status, n (%)   
     Fasting (≥ 6 hours) 117 (28) 113 (27) 
     In between (3 - 6 hours) 158 (37) 163 (39) 
     Non fasting (< 3 hours) 66 (16) 66 (15) 
     Unknown 81 (19) 80 (19) 
Self-reported diabetes at recruitment, n (%) 30 (7) 17 (4) 
Subjects HbA1c ≥ 6.5%, n (%) 50 (12) 28 (7) 
   
C-peptide [ng/mL], mean ± SD 6.98 ± 4.6 6.66 ± 4.5 
IGF-1 [ng/mL], mean ± SD 184.8 ± 71.3 182.5 ± 68.5 
     Male 187.1 ± 74.1 185.7 ± 68.3 
     Female 182.9 ± 68.9 179.7 ± 68.7 
IGFBP-3 [ng/mL],mean ± SD 4668 ± 1209 4665 ± 1085 
     Male 4411 ± 1267 4484 ± 1042 
     Female 4890 ± 1114 4821 ± 1100 
IGF-1 / IGFBP-3 ratio 0.19 ± 0.06 0.18 ± 0.06 
SD = standard deviation, IQR = interquartile range 
1 Percentages do not add up to 100% because not all subgroups are shown 
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Table 2.Relative risk [OR (95% CI)] of pancreatic cancer by quartiles of IGF-1, IGFBP-3, and its ratio in EPIC 
 Quartiles1  OR  
 1 2 3 4 Ρ trend2 continuous P trend3 
IGF-1 men [ng/ml] 33 - 138 139 - 176 177 - 226 227 - 437  per 10 ng/mL  
IGF-1 women [ng/ml] 40 - 128 129 - 168 169 - 220 221 - 433    
No. cases / controls 103 / 104 88 / 105 115 / 106 114 / 105    
Model 14 1.0 0.88 (0.58-1.31) 1.17 (0.76-1.81) 1.21 (0.75-1.93) 0.301 1.01 (0.98-1.04) 0.499 
Model 25 1.0 0.88 (0.58-1.34) 1.21 (0.77-1.90) 1.14 (0.70-1.85) 0.475 1.01 (0.98-1.04) 0.526 
Model 36 1.0 0.88 (0.58-1.35) 1.23 (0.78-1.94) 1.15 (0.70-1.88) 0.469 1.01 (0.98-1.04) 0.460 
Model 47 1.0 0.86 (0.55-1.35) 1.21 (0.74-1.98) 1.13 (0.67-1.92) 0.542 1.01 (0.98-1.04) 0.721 
Model 58 1.0 0.89 (0.56-1.42) 1.27 (0.75-2.14) 1.21 (0.66-2.25) 0.439 1.01 (0.97-1.05) 0.597 
        
IGFBP-3 men [ng/ml] 1625 - 3800 3825 - 4548 4550 - 5057 5092 - 9367  per 100 ng/mL  
IGFBP-3 women [ng/ml] 1698 - 4085 4087 - 4740 4745 - 5321 5342 - 11,128    
No. cases / controls 114 / 104 107 / 106 84 / 106 116 / 105    
Model 14 1.0 0.90 (0.60-1.36) 0.72 (0.48-1.08) 1.00 (0.66-1.51) 0.789 1.00 (0.99-1.01) 0.954 
Model 25 1.0 1.00 (0.65-1.52) 0.75 (0.49-1.14) 1.13 (0.73-1.74) 0.812 1.00 (0.99-1.02) 0.593 
Model 36 1.0 1.04 (0.67-1.59) 0.76 (0.49-1.17) 1.06 (0.68-1.65) 0.941 1.00 (0.99-1.01) 0.970 
Model 47 1.0 1.05 (0.67-1.65) 0.81 (0.52-1.27) 1.07 (0.67-1.71) 0.969 1.00 (0.99-1.02) 0.696 
Model 59 1.0 1.00 (0.63-1.59) 0.76 (0.47-1.23) 0.94 (0.55-1.61) 0.673 1.00 (0.98-1.02) 0.875 
        
IGF-I/IGFBP-3 men 0.05 - 0.15 0.16 - 0.18 0.19 - 0.22 0.22- 0.43  per 0.01  
IGF-I/IGFBP-3 women 0.05 - 0.12 0.13 - 0.16 0.17 - 0.21 0.22 - 0.44    
No. cases / controls 103 / 104 88 / 105 112 / 105 116 / 105    
Model 14 1.0 0.87 (0.57-1.33) 1.12 (0.73-1.72) 1.22 (0.75-1.97) 0.273 1.02 (0.99-1.05) 0.190 
Model 25 1.0 0.86 (0.55-1.33) 1.10 (0.70-1.70) 1.12 (0.68-1.85) 0.480 1.01 (0.98-1.04) 0.425 
Model 36 1.0 0.96 (0.61-1.52) 1.21 (0.77-1.90) 1.29 (0.77-2.16) 0.245 1.02 (0.99-1.05) 0.207 
Model 47 1.0 0.94 (0.59-1.51) 1.14 (0.71-1.84) 1.17 (0.69-2.00) 0.467 1.01 (0.98-1.04) 0.594 
CI=confidence interval, No=number 
1 quartile cut points were based on the distribution of controls 
2 P trend test was based on median values of each quartile 
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3 P trend test was based on continuous values 
4 Model 1: logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood 
sampling and last consumption of foods and drinks).  
5 Model 2: as model 1 with further adjustment for smoking (never, former, quitting smoking less than 10 years ago, more than 10 years ago, current, with 1-9, 
10-19, or ≥ 20 cigarettes per day, missing),  
6 Model 3: as above with further adjustment for BMI (continuous) and diabetes (defined by self-report or HbA1c concentration ≥ 6.5%),  
7 Model 4: as above with further adjustment for C-peptide concentration (continuous) 
8 Model 5: as above with further adjustment for IGFBP-3 concentration (continuous) 
9 Model 5: as model 3 with further adjustment for IGF-I concentration (continuous) 
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Table 3. Relative risk [OR (95% CI)] of pancreatic cancer by quartiles of IGF-1, IGFBP-3, and its ratio for subgroups in EPIC 
 
 No Quartiles1  
 Ca / Co 1 2 3 4 p-trend2 p-interaction 
        
IGF-1 men [ng/ml] 195 / 195 33 - 138 139 - 176 177 - 226 227 - 437   
IGF-1 women [ng/ml] 225 / 227 40 - 128 129 - 168 169 - 220 221 - 433   
        
Non-smoker 154 / 189 1.0 1.09 (0.57-2.07) 1.63 (0.85-3.13) 1.72 (0.91-3.28) 0.068 0.445 
Smokers 261 / 228 1.0 0.73 (0.42-1.26) 0.98 (0.57-1.68) 0.94 (0.54-1.64) 0.878  
        
Non-diabetics 349 / 374 1.0 0.88 (0.56-1.37) 1.23 (0.80-1.91) 1.20 (0.77-1.88) 0.244 0.545 
Diabetics 54 / 32 1.0 1.54 (0.40-5.99) 0.69 (0.14-3.32) 0.81 (0.18-3.75) 0.629  
        
Years 1&2 of fup 71 / 71 1.0 0.59 (0.17-2.04) 1.09 (0.29-4.09) 1.43 (0.36-5.69) 0.417 0.946 
3+ years of fup 349 / 351 1.0 0.93 (0.58-1.48) 1.26 (0.77-2.08) 1.22 (0.71-2.11) 0.391  
        
Male 195 / 195 1.0 0.71 (0.37-1.35) 1.18 (0.59-2.37) 1.09 (0.53-2.23) 0.553 0.746 
Female 225 / 227 1.0 1.09 (0.60-1.98) 1.28 (0.68-2.42) 1.08 (0.52-2.25) 0.827  
        
Low C-peptide 214 / 221 1.0 0.64 (0.37-1.12) 0.85 (0.48-1.51) 1.08 (0.59-1.95) 0.513 0.398 
High C-peptide 206 / 201 1.0 1.15 (0.61-2.14) 1.57 (0.87-2.84) 1.27 (0.71-2.29) 0.396  
        
Low waist circumference 205 / 221 1.0 0.83 (0.46-1.52) 1.80 (1.01-3.23) 1.23 (0.68-2.23) 0.246 0.040 
High waist circumference 215 / 201 1.0 0.79 (0.44-1.41) 0.70 (0.38-1.27) 1.03 (0.56-1.86) 0.812  
        
Microscopically confirmed 305 / 307 1.0 0.95 (0.57-1.58) 1.45 (0.83-2.52) 1.10 (0.61-2.00) 0.632    
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Table 3 cont. 
 
 No Quartiles1  
 Ca / Co 1 2 3 4 p-trend2 p-interaction 
        
IGFBP-3 men [ng/ml] 195 / 195 1625 - 3800 3825 - 4548 4550 - 5057 5092 - 9367   
IGFBP-3 women [ng/ml] 227 / 226 1698 - 4085 4087 - 4740 4745 - 5321 5342 - 11128   
        
Non-smoker 155 / 189 1.0 1.00 (0.53-1.89) 0.77 (0.40-1.47) 0.94 (0.50-1.79) 0.701 0.974 
Smokers 262 / 227 1.0 0.94 (0.55-1.59) 0.73 (0.42-1.26) 1.05 (0.62-1.77) 0.987  
        
Non-diabetics 351 / 373 1.0 1.02 (0.67-1.55) 0.69 (0.44-1.08) 0.99 (0.64-1.52) 0.622 0.694 
Diabetics  54 / 32 1.0 0.61 (0.13-2.82) 1.13 (0.25-5.16) 1.12 (0.27-4.61) 0.797  
        
Years 1&2 of fup 71 / 70 1.0 1.68 (0.59-4.78) 1.36 (0.44-4.23) 1.44 (0.46-4.47) 0.612 0.724 
3+ years of fup 351 / 351 1.0 0.94 (0.58-1.52) 0.69 (0.43-1.13) 1.12 (0.68-1.85) 0.855  
        
Male 195 / 195 1.0 0.78 (0.41-1.46) 0.54 (0.28-1.04) 0.96 (0.50-1.84) 0.774 0.362 
Female 227 / 226 1.0 1.37 (0.74-2.56) 1.03 (0.56-1.90) 1.17 (0.61-2.25) 0.915  
        
Low c-peptide 215 / 221 1.0 0.78 (0.45-1.35) 0.66 (0.37-1.16) 0.64 (0.36-1.14) 0.088 0.198 
High c-peptide 207 / 200 1.0 1.21 (0.66-2.23) 0.78 (0.42-1.45) 1.47 (0.82-2.65) 0.277  
        
Low waist circumference 206 / 221 1.0 0.74 (0.43-1.30) 0.57 (0.32-1.02) 0.92 (0.51-1.63) 0.632 0.654 
High waist circumference 216 / 200 1.0 1.26 (0.69-2.27) 0.91 (0.49-1.68) 1.05 (0.59-1.87) 0.825  
        
Microscopically confirmed 307 / 306 1.0 0.98 (0.57-1.66) 0.65 (0.38-1.12) 0.94 (0.55-1.62) 0.624    
28 
 
 
Table 3 cont. 
 
 No Quartiles1  
 Ca / Co 1 2 3 4 p-trend2 p-interaction 
        
IGF-I/IGFBP-3 men 195 / 195 0.05 - 0.15 0.16 - 0.18 0.19 - 0.22 0.22- 0.43   
IGF-I/IGFBP-3 women 225 / 226 0.05 - 0.12 0.13 - 0.16 0.17 - 0.21 0.22 - 0.44   
        
Non-smoker 154 / 189 1.0 1.08 (0.56-2.11) 1.54 (0.81-2.92) 1.83 (0.94-3.57) 0.052 0.683 
Smokers 261 / 227 1.0 0.81 (0.47-1.39) 1.03 (0.60-1.75) 1.16 (0.67-1.99) 0.442  
        
Non-diabetics 349 / 373 1.0 1.02 (0.65-1.59) 1.27 (0.82-1.97) 1.39 (0.89-2.17) 0.097 0.543 
Diabetics  54 / 32 1.0 0.28 (0.06-1.29) 1.00 (0.25-4.08) 0.91 (0.18-4.59) 0.923  
        
Years 1&2 of follow-up 71 / 70 1.0 1.23 (0.26-5.75) 2.05 (0.38-11.08) 0.85 (0.18-4.03) 0.761 0.513 
3+ years of follow-up 349 / 351 1.0 1.01 (0.62-1.63) 1.20 (0.75-1.94) 1.45 (0.83-2.54) 0.163  
        
Male 195 / 195 1.0 0.49 (0.24-0.98) 1.07 (0.55-2.08) 1.28 (0.62-2.64) 0.161 0.050 
Female 225 / 226 1.0 1.45 (0.76-2.77) 1.31 (0.67-2.55) 1.18 (0.52-2.65) 0.856  
        
Low C-peptide 214 / 221 1.0 0.64 (0.36-1.16) 0.91 (0.50-1.64) 1.20 (0.67-2.17) 0.254 0.423 
High C-peptide 206 / 200 1.0 1.42 (0.78-2.60) 1.33 (0.77-2.32) 1.35 (0.75-2.45) 0.370  
        
Low waist circumference 205 / 221 1.0 0.85 (0.46-1.56) 1.73 (0.94-3.17) 1.33 (0.73-2.39) 0.162 0.028 
High waist circumference 215 / 200 1.0 1.01 (0.56-1.81) 0.75 (0.43-1.30) 1.35 (0.74-2.48) 0.491  
        
Microscopically confirmed 305 / 306 1.0 1.25 (0.72-2.18) 1.52 (0.88-2.61) 1.49 (0.81-2.72) 0.195  
1 Logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood 
sampling and last consumption of foods and drinks) and adjusted for smoking (never, former, quitting smoking less than 10 years ago, more than 10 years 
ago, current, with 1-9, 10-19, or ≥ 20 cigarettes per day, missing), BMI (continuous) and diabetes (defined by self-report or HbA1c concentrations ≥ 6.5%) 
2 P trend test was based on median values of each quartile 
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Table 4. Joint effect of IGF-1 and IGFBP-3 concentrations on risk of pancreatic 
cancer [OR (95% CI)] 
 
 < median IGF-1 ≥ median IGF-1 
   
   
≥ median IGFBP-3 1.0 1.48 (0.97-2.22) 
   
< median IGFBP-3 1.47 (0.97-2.22) 1.72 (1.05-2.83) 
   
 
1 Logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at 
recruitment, date at entry in the cohort, time between blood sampling and last consumption of 
foods and drinks) and adjusted for smoking (never, former, quitting smoking less than 10 years 
ago, more than 10 years ago, current, with 1-9, 10-19, or ≥ 20 cigarettes per day, missing), BMI 
(continuous) and diabetes (defined by self-report or HbA1c concentrations ≥ 6.5%) 
2 P-interaction = 0.154 
